WestVac Biopharma
WestVacBiopharmaisfoundedbyAcademicianWeiYuquanfromWestChinaHospitalofSichuanUniversity,togetherwith10scientistsfromStateKeyLaboratoryofBiotherapy(SKLB).ItsheadquarterislocatedintheInternationalBio-Town,Chengdu.TheCEOofWestVacBiopharmaisProf.WeiYuquan,whoistheAcademicianofChineseAcademyofSciencesaswellastheDirectorofStateKeyLaboratoryofBiotherapy.WestVaciscommittedtoexploringthelatestbiotherapytechnologiesformajordiseases,includinginfectiousdiseases,malignanttumors,cardiovasculardiseases,andsoon.IthasattachedgreatimportanceintheResearchandDevelopment(R&D)ofCOVID-19vaccineespeciallyandbuildingaCOVID-19vaccineproductionplatform.StateKeyLaboratoryofBiotherapy(SKLB)wasestablishedbytheMinistryofSciencesandTechnologyofChinain2005andbecameoneoftheNationalR&DPlatformsforNovelDrugsfoundedbytheMinistriesofSciencesandTechnologyaswellasthatofHealthofChinain2008.ItisalsosupportedbyNationalCollaborativeInnovationProgramandhasbecometheNationalCollaborativeInnovationCenterforBiotherapysince2013.WestChinaHospitalofSichuanUniversity,foundedin1892,istheNationalCenterforDiagnosisandTreatmentofSevereandCriticalDiseasesinWesternChina.Itisalsotheworld’slargestcomprehensivehospitalcomplexlocatedinonecampusarea.RelyingonthemedicalresourcesofStateKeyLaboratoryofBiotherapyandWestChinaMedicalCenter,WestVachasadoptedrecombinantproteinmethodologytodeveloptheCOVID-19vaccine.Becauseofthesafetyoftheproteinvaccine,itisalsotheonlyCOVID-19vaccineapprovedfortheuseinchildrenover3yearsoldinChina.ThevaccinewasapprovedbytheNationalMedicalProductsAdministrationforclinicaltrialsonAugust21,2020.PhaseI/IIclinicaltrialshavebeencompleted,andphaseIIIclinicaltrialsarebeingcarriedoutinNepal,Kenya,Japanandothercountries.Thevaccinetargetsthespikeproteinbindingdomain(S-RBD)ofSARS-CoV-2,producingneutralizingantibodiestoblockCOVID-19infectionofhumancells.TheresultwaspublishedonNature,theworld’sfamousscientificjournalonJuly29th,2020.IthasalsobeenthefirstpaperofCOVIDvaccinepublishedbyNaturesincethepandemicoutbreak.TheS-RBDgeneoftheCOVID-19virusisintroducedintotheinsectcells,whichwereusedasafactorytoproducehigh-qualityrecombinantvaccineproteinandthendoesrefinedpurification.Suchtechnologyiseasytobemass-producedandbroughttothemarket.WestVacBiopharmaiscommittedtobecomingtheworld`sleadingvaccineandimmunotherapyplatform.
华川建设集团有限公司(简称“华川集团”)前身为广东华川建设工程有限公司,始于2010年3月注册,注册资金为11800万元。华川建设集团是一家以建筑施工总承包(一级资质)、市政公用工程施工总承包(二级资质)为主,集水利水电、电力、公路、机电设备安装、城市及道路照明、钢结构、地基与基础、输变电、城市园林绿化、古建筑工程,以及环保、地质灾害治理、电子智能化、消防设施安装、建筑装饰装修设计与施工、建筑幕墙、建筑科技研发与推广、建材贸易和建筑设备租赁及对外投资于一体的综合型企业集团。公司自2010年3月成立以来,连续十一年获得“广东省守合同重信用企业”荣誉;连续三年被东莞市税务局评定为纳税信用A级纳税人。2018年获得“高新技术企业”认证,2021年再次获得“高新技术企业”认定。公司荣获东莞市东城街道2018年倍增计划试点企业、2019年度“提前实现(规模和效益)倍增奖”和2020年东莞市协同倍增企业;2019、2020年连续两年获得东莞市建筑业产值百强企业”;2019、2020、2021年连续三年获得“东莞市建设行业企业量化评价先进企业”;2020、2021连续两年获得“东莞建造”优质施工企业名录等荣誉;2020年